Share

April 2015; 2 (2) ArticleOpen Access

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally

Anders Svenningsson, Joakim Bergman, Ann Dring, Mattias Vågberg, Richard Birgander, Thomas Lindqvist, Jonathan Gilthorpe, Tommy Bergenheim
First published February 26, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000079
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1411

Share

Article Information

vol. 2 no. 2 e79
DOI: 
https://doi.org/10.1212/NXI.0000000000000079
PubMed: 
25745637
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 8, 2014
  • Accepted in final form January 13, 2015
  • First Published February 26, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Anders Svenningsson, MD,
    2. Joakim Bergman, MSc,
    3. Ann Dring, PhD,
    4. Mattias Vågberg, MD,
    5. Richard Birgander, MD,
    6. Thomas Lindqvist, MD,
    7. Jonathan Gilthorpe, PhD and
    8. Tommy Bergenheim, MD
  1. Anders Svenningsson, MD,
    2. Scientific Advisory Boards:

    1. Served in advisory board for Sanofi-Genzyme and BiogenIdec

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1. Travel and congress expenses paid for by BiogenIdec, Sanofi-Genzyme, Novartis and Baxter Medical 2. Speaker honoraria from BiogenIdec, Sanofi-Genzyme and Baxter

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received non-conditional research grants from BiogenIdec

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Joakim Bergman, MSc,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ann Dring, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Ume? university, post-doctoral researcher employed by Anders Svenningsson

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Mattias Vågberg, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1)BiogenIdec, speaker honoriaria, (2)BiogenIdec, travel support to scientific meeting, (3)Novartis, travel support to scientific meeting, (4)Baxter Medical, travel support to scientific meeting, (5)Pharma Industry, writing honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)BiogenIdec

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)Neuro Sweden

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Richard Birgander, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Thomas Lindqvist, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Jonathan Gilthorpe, PhD and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Tommy Bergenheim, MD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Swedish Cancer Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Pharmacology and Clinical Neuroscience (A.S., J.B., A.D., M.V., J.G., T.B.) and Department of Radiation Sciences (R.B., T.L.), Diagnostic Radiology, Umeå University, Sweden.
  1. Correspondence to Dr. Svenningsson: anders.svenningsson{at}neuro.umu.se
View Full Text

Article usage

Article usage: March 2015 to April 2023

AbstractFullPdfSource
Feb 20152232Highwire
Mar 20152243034Highwire
Mar 20150127102pmc
Apr 201539326786Highwire
Apr 201504124pmc
May 2015833213Highwire
May 201503013pmc
Jun 2015964620Highwire
Jun 201503417pmc
Jul 201563816Highwire
Jul 201502728pmc
Aug 2015951018Highwire
Aug 201501627pmc
Sep 201557368Highwire
Sep 201502428pmc
Oct 2015481017Highwire
Oct 201503635pmc
Nov 201524114Highwire
Nov 201502827pmc
Dec 20152962Highwire
Dec 20150912pmc
Jan 201636107Highwire
Jan 201602219pmc
Feb 201624610Highwire
Feb 201602526pmc
Mar 20162268Highwire
Mar 201602824pmc
Apr 20162862Highwire
Apr 201602213pmc
May 20163293Highwire
May 20160149pmc
Jun 20163189Highwire
Jun 201602015pmc
Jul 20162887Highwire
Jul 201602416pmc
Aug 20162948Highwire
Aug 20160213pmc
Sep 201627113Highwire
Sep 20160146pmc
Oct 2016491017Highwire
Oct 201601310pmc
Nov 20162225Highwire
Nov 201602131pmc
Dec 201624135Highwire
Dec 2016064pmc
Jan 201736511Highwire
Jan 20170188pmc
Feb 201725213Highwire
Feb 201701112pmc
Mar 201736811Highwire
Mar 20170209pmc
Apr 20172253Highwire
Apr 201731212pmc
May 201712143Highwire
May 201771415pmc
Jun 201710174Highwire
Jun 201792023pmc
Jul 20171491Highwire
Jul 20177127pmc
Aug 201715231Highwire
Aug 2017465pmc
Sep 2017984Highwire
Sep 201741010pmc
Oct 201714195Highwire
Oct 201741110pmc
Nov 20171024Highwire
Nov 201741113pmc
Dec 20170134Highwire
Jan 2018885Highwire
Feb 20181131Highwire
Mar 20184183Highwire
Apr 2018293Highwire
Apr 2018121820pmc
May 20186272Highwire
Jun 20185152Highwire
Jun 2018466pmc
Jul 20182168Highwire
Aug 20182273Highwire
Aug 201832125pmc
Sep 20182333Highwire
Oct 20181396Highwire
Nov 20182590Highwire
Dec 20184923Highwire
Jan 20194941Highwire
Feb 201912963Highwire
Mar 20194455Highwire
Apr 20194137Highwire
May 20199183Highwire
Jun 20196174Highwire
Jul 20194215Highwire
Aug 2019596Highwire
Sep 2019183Highwire
Oct 20196154Highwire
Nov 20196413Highwire
Dec 20195120Highwire
Jan 20203206Highwire
Feb 20202154Highwire
Mar 20201288Highwire
Apr 20201102Highwire
May 20202134Highwire
Jun 20203176Highwire
Jul 2020360Highwire
Aug 2020155Highwire
Sep 20206218Highwire
Oct 20200296Highwire
Nov 20203912Highwire
Dec 202032220Highwire
Jan 20219249Highwire
Feb 20211127Highwire
Mar 2021385Highwire
Apr 20219171Highwire
May 20215135Highwire
Jun 20212175Highwire
Jul 20218910Highwire
Aug 20212165Highwire
Sep 20211813Highwire
Oct 202162019Highwire
Nov 20212921Highwire
Dec 20214226Highwire
Jan 2022281Highwire
Feb 202252012Highwire
Mar 20225125Highwire
Apr 2022382Highwire
May 202231712Highwire
Jun 20226165Highwire
Jul 20221171Highwire
Aug 20224234Highwire
Sep 20224348Highwire
Oct 202252311Highwire
Nov 202286116Highwire
Dec 20222308Highwire
Jan 20237536Highwire
Feb 20235317Highwire
Mar 20230214Highwire
Apr 2023197Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles